EA200970471A1 - Микроорганизмы или их фракции, обеспечивающие активацию клеточного иммунитета против углеводов - Google Patents
Микроорганизмы или их фракции, обеспечивающие активацию клеточного иммунитета против углеводовInfo
- Publication number
- EA200970471A1 EA200970471A1 EA200970471A EA200970471A EA200970471A1 EA 200970471 A1 EA200970471 A1 EA 200970471A1 EA 200970471 A EA200970471 A EA 200970471A EA 200970471 A EA200970471 A EA 200970471A EA 200970471 A1 EA200970471 A1 EA 200970471A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- microorganisms
- fractions
- ensuring
- activation
- immunity against
- Prior art date
Links
- 230000004913 activation Effects 0.000 title 1
- 150000001720 carbohydrates Chemical class 0.000 title 1
- 235000014633 carbohydrates Nutrition 0.000 title 1
- 230000007969 cellular immunity Effects 0.000 title 1
- 244000005700 microbiome Species 0.000 title 1
- 230000002265 prevention Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
Abstract
Настоящее изобретение относится к профилактике и лечению желудочно-кишечных расстройств и рака. В частности, изобретение относится к профилактике и лечению карцином, которые являются Core-1-положительными. Это изобретение касается кориотиков и способа их получения, а также способа предотвращения и лечения Core-1-положительных расстройств, используя эти кориотики.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06090208.7A EP1920781B1 (en) | 2006-11-10 | 2006-11-10 | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors |
EP06090209A EP1920782A1 (en) | 2006-11-10 | 2006-11-10 | Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof |
PCT/EP2007/009766 WO2008055703A2 (en) | 2006-11-10 | 2007-11-12 | Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200970471A1 true EA200970471A1 (ru) | 2009-12-30 |
EA025395B1 EA025395B1 (ru) | 2016-12-30 |
Family
ID=39200183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970471A EA025395B1 (ru) | 2006-11-10 | 2007-11-12 | Core-1 положительные микроорганизмы или их фракции, обеспечивающие активацию клеточного иммунитета против углеводов |
Country Status (18)
Country | Link |
---|---|
US (2) | US9494587B2 (ru) |
EP (4) | EP1920782A1 (ru) |
JP (4) | JP2010508834A (ru) |
KR (2) | KR20150054014A (ru) |
CN (1) | CN101573138B (ru) |
AU (2) | AU2007316820B2 (ru) |
BR (2) | BRPI0719005A2 (ru) |
CA (2) | CA2668603A1 (ru) |
EA (1) | EA025395B1 (ru) |
ES (1) | ES2715045T3 (ru) |
HK (1) | HK1136219A1 (ru) |
IL (2) | IL198567A0 (ru) |
MX (1) | MX2009005004A (ru) |
NO (1) | NO20091748L (ru) |
NZ (1) | NZ577559A (ru) |
PL (1) | PL1920781T3 (ru) |
RU (1) | RU2460074C2 (ru) |
WO (2) | WO2008055702A1 (ru) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2662226C (en) | 2006-09-10 | 2020-08-04 | Glycotope Gmbh | Fully human high yield production system for improved antibodies and proteins |
EP1920782A1 (en) * | 2006-11-10 | 2008-05-14 | Glycotope Gmbh | Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof |
CA2722738C (en) | 2008-05-13 | 2017-04-25 | Glycotope Gmbh | Fermentation process |
EP2119365B1 (de) | 2008-05-13 | 2017-08-16 | Glycotope GmbH | Fermentationsprozess |
AU2010281507A1 (en) * | 2009-07-27 | 2012-03-01 | The University Of North Carolina At Chapel Hill | Enterococcus and fecal Bacteroides for rapid water quality assessment |
GB2475226A (en) | 2009-11-03 | 2011-05-18 | Genetic Analysis As | Universal Prokaryote 16S ribosome PCR primer pair |
CN102947441A (zh) * | 2010-06-01 | 2013-02-27 | 穆尔研究企业有限责任公司 | 来自拟杆菌属的细胞组分、其组合物和使用拟杆菌或其细胞组分的治疗方法 |
KR20140033309A (ko) * | 2010-10-04 | 2014-03-18 | 브리티쉬 콜롬비아 캔써 에이전시 브랜치 | 위장 암을 진단하기 위해 위장의 샘플에서의 푸소박테리움의 검출 |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
US9700610B2 (en) | 2011-08-22 | 2017-07-11 | Glycotope Gmbh | Microorganisms carrying a tumor antigen |
JP2014524260A (ja) * | 2011-08-22 | 2014-09-22 | グリコトープ ゲーエムベーハー | Bacteroidesxylanisolvens種の微生物 |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
JP6254585B2 (ja) * | 2012-06-26 | 2017-12-27 | セントル ホスピタリエ リージョナル ユニヴェルシテール ドゥ リールCentre Hospitalier Regional Universitaire de Lille | Maldi−tof質量分析による侵襲性真菌感染症の体外診断法 |
CN102813916B (zh) * | 2012-09-05 | 2015-03-11 | 北京希普生国际生物医学研究院 | 一种快速获取树突状细胞疫苗的制备方法及其应用 |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
EP2818056A1 (en) * | 2013-06-25 | 2014-12-31 | Biosearch S.A. | Probiotic bacteria comprising metals, metal nanoparticles and uses thereof |
CN113717964A (zh) * | 2013-08-06 | 2021-11-30 | 达特茅斯学院理事会 | 非糖基化溶葡球菌素变体蛋白 |
SG11201607258SA (en) | 2014-04-10 | 2016-10-28 | Obi Pharma Inc | Antibodies, pharmaceutical compositions and uses thereof |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
CN104546932A (zh) * | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
CN104546933A (zh) * | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 粪拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
LT3065748T (lt) | 2014-12-23 | 2018-03-12 | 4D Pharma Research Limited | Bacteroides thetaiotaomicron padermė ir jos panaudojimas uždegimo sumažinimui |
HUE037476T2 (hu) * | 2014-12-23 | 2018-08-28 | 4D Pharma Res Ltd | Pirin polipeptid és immunmodulálás |
US10076556B2 (en) * | 2015-01-29 | 2018-09-18 | Oxyrase, Inc. | Methods for inhibiting tumor growth |
EP3636272A1 (en) | 2015-06-15 | 2020-04-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
LT3650033T (lt) | 2015-06-15 | 2022-04-11 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterinius kamienus |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
RS59308B1 (sr) | 2015-06-15 | 2019-10-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB2561748B (en) | 2015-11-20 | 2019-05-08 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
TW201733601A (zh) | 2016-03-04 | 2017-10-01 | 4D製藥有限公司 | 包含細菌菌株之組合物 |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
CN109475169A (zh) * | 2016-07-01 | 2019-03-15 | 进化生物系统股份有限公司 | 促进哺乳动物免疫系统成熟的方法 |
TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
EP3378949A1 (en) * | 2017-03-22 | 2018-09-26 | Assistance Publique - Hôpitaux de Paris | Method for determining the potential efficacy of anticancer treatment |
MA48940A (fr) | 2017-05-22 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
MD3638271T2 (ro) | 2017-06-14 | 2021-03-31 | 4D Pharma Res Ltd | Compoziții cuprizând tulpini bacteriene |
DK3804737T3 (da) | 2017-06-14 | 2022-07-25 | 4D Pharma Res Ltd | Sammensætninger omfattende bakteriestammer |
AR112328A1 (es) | 2017-07-05 | 2019-10-16 | Evelo Biosciences Inc | Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis |
CA3100608A1 (en) | 2018-05-18 | 2019-11-21 | Daiichi Sankyo Co., Ltd. | Anti-muc1 antibody-drug conjugate |
CA3146738A1 (en) * | 2019-07-18 | 2021-01-21 | Synthetic Biologics, Inc. | Intestinal alkaline phosphatase-based treatments of metabolic disorders |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4672316A (en) | 1983-08-19 | 1987-06-09 | Werkzeugmaschinenfabrik Oerlikon-Buhrle Ag | Method for calibrating a muzzle velocity measuring device |
KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
US4931275A (en) * | 1985-12-02 | 1990-06-05 | Yeda Research & Development Co., Ltd. | Anti-tumor vaccines and their preparation |
US5683674A (en) * | 1987-01-07 | 1997-11-04 | Imperial Cancer Research Technology Ltd. | Antibody against human mucin core protein and method of preparing and using same |
DE68928665T2 (de) | 1988-08-02 | 1998-11-12 | Gastro Services Pty Ltd | Behandlung von gastro-intestinalen krankheiten |
US5110911A (en) | 1989-11-02 | 1992-05-05 | Biomira, Inc. | Human tumor-associated thomsen-friedenreich antigen |
AU664030B2 (en) | 1991-02-27 | 1995-11-02 | Micromet Ag | Serine-rich peptide linkers |
CA2118010C (en) * | 1992-04-13 | 2003-10-28 | Donald Kufe | Antibodies specific for carcinoma-associated antigens |
US5804187A (en) * | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
US5910488A (en) | 1993-06-07 | 1999-06-08 | Vical Incorporated | Plasmids suitable for gene therapy |
DE4329004A1 (de) | 1993-08-28 | 1995-03-09 | Max Delbrueck Centrum | Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis |
US7137011B1 (en) * | 1993-09-01 | 2006-11-14 | Sandisk Corporation | Removable mother/daughter peripheral card |
US5997873A (en) * | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US5961979A (en) * | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
US5772995A (en) * | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
JP2660175B2 (ja) * | 1994-10-19 | 1997-10-08 | 北海道 | キクイモ由来のレクチンおよびその分離精製法 |
US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
WO1997000957A1 (en) | 1995-06-23 | 1997-01-09 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
WO1997024130A1 (fr) * | 1995-12-27 | 1997-07-10 | Ngk Insulators, Ltd. | INHIBITEUR DE METASTASES CANCEREUSES CONTENANT UN POLYSACCHARIDE DE SURFACE DE STREPTOCOCCUS AGALACTIAE DE TYPE Ia OU DE TYPE Ib COMME COMPOSANT PRINCIPAL |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
EP0906444A1 (de) | 1996-04-19 | 1999-04-07 | Gabriele Pecher | Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine |
CA2641217A1 (en) * | 1997-11-20 | 1999-06-03 | Vical Incorporated | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor |
US5948646A (en) * | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
KR100425965B1 (ko) * | 1998-02-20 | 2004-04-06 | 타녹스 인코퍼레이티드 | 보체 활성화의 억제물질 |
JP2000028599A (ja) * | 1998-04-15 | 2000-01-28 | Ebara Corp | D―マンノ―ス識別アフィニティ―担体とその使用方法 |
EP1399538A4 (en) | 1999-03-02 | 2004-03-24 | Human Genome Sciences Inc | TECHOLOGICAL MANIPULATION OF INTRACELLULAR SIALIZATION PATHS |
DK1167537T3 (da) | 1999-03-30 | 2008-11-10 | Japan Tobacco Inc | Fremgangsmåde til fremstilling af et monoklonalt antistof |
AU782569B2 (en) | 1999-08-18 | 2005-08-11 | Oncoquest Inc. | Therapeutic binding agents against MUC-1 antigen and methods of their use |
US7147850B2 (en) * | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
JP2003510334A (ja) * | 1999-09-30 | 2003-03-18 | コリクサ コーポレイション | 癌及び感染症の予防及び治療のためのストレスタンパク質組成物及び方法 |
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
US20030138769A1 (en) * | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
GB0029360D0 (en) | 2000-12-01 | 2001-01-17 | Univ Nottingham | Humanised antibodies and uses thereof |
AU2002354804A1 (en) * | 2001-07-06 | 2003-01-21 | Sloan-Kettering Institute For Cancer Research | Polyvalent conjugate vaccine for cancer |
EP1419176A2 (en) | 2001-08-17 | 2004-05-19 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Glycoconjugates of sialic acid derivates, methods for their production and use thereof |
DE10139428A1 (de) | 2001-08-17 | 2003-03-27 | Nemod Immuntherapie Ag | Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika |
GB0125473D0 (en) | 2001-10-24 | 2001-12-12 | Syngenta Ltd | Chemical process |
CN1201817C (zh) * | 2001-11-09 | 2005-05-18 | 北京大学肝病研究所 | 一种治疗肝癌的肿瘤ct抗原免疫诱导剂及其制备方法 |
CA2468088A1 (en) | 2001-11-20 | 2003-05-30 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
WO2004009632A2 (de) | 2002-07-22 | 2004-01-29 | Nemod Immuntherapie Ag | Verfahren zur herstellung eines immunstimulatorischen muzins (muc1) |
DE60334382D1 (de) * | 2002-08-16 | 2010-11-11 | Glycotope Gmbh | Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen |
AU2003275990A1 (en) * | 2002-09-26 | 2004-04-19 | Novartis Ag | Tcell mediator/modulator assay based upon tcell restricted transgenic mouse |
DE10256900A1 (de) * | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
US8389278B2 (en) * | 2003-02-27 | 2013-03-05 | Northwest Biotherapeutics, Inc. | Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines |
GB0315991D0 (en) | 2003-07-08 | 2003-08-13 | Dakocytomation Denmark As | Standard |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
PT1654353E (pt) | 2003-08-18 | 2013-08-23 | Glycotope Gmbh | Linhas de células tumorais nm f9 (dsm acc2606) e nm d4 (dsm acc2605), suas utilizações |
FR2861080B1 (fr) | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
US8609370B2 (en) * | 2004-02-13 | 2013-12-17 | Glycotope Gmbh | Highly active glycoproteins-process conditions and an efficient method for their production |
WO2005108423A1 (en) | 2004-05-11 | 2005-11-17 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
US20080193440A1 (en) * | 2004-07-01 | 2008-08-14 | Kobenhavns Universitet | Method For Multiple Sclerosis Treatment and Prophylaxis By Treatment of Leptospira Infection |
CA2582252C (en) * | 2004-07-26 | 2014-08-26 | The Research Foundation Of State University Of New York | Therapeutic use of anti-tf-antigen antibody |
AU2006275510B2 (en) * | 2005-08-01 | 2013-02-21 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada. | Low fiber yellow canola seeds comprising high oleic, low linolenic oil |
CA2662226C (en) * | 2006-09-10 | 2020-08-04 | Glycotope Gmbh | Fully human high yield production system for improved antibodies and proteins |
EP1920782A1 (en) * | 2006-11-10 | 2008-05-14 | Glycotope Gmbh | Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof |
CA2722738C (en) * | 2008-05-13 | 2017-04-25 | Glycotope Gmbh | Fermentation process |
EP2281844A1 (en) * | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
US9700610B2 (en) * | 2011-08-22 | 2017-07-11 | Glycotope Gmbh | Microorganisms carrying a tumor antigen |
-
2006
- 2006-11-10 EP EP06090209A patent/EP1920782A1/en not_active Withdrawn
- 2006-11-10 EP EP06090208.7A patent/EP1920781B1/en active Active
- 2006-11-10 PL PL06090208T patent/PL1920781T3/pl unknown
-
2007
- 2007-11-12 JP JP2009535633A patent/JP2010508834A/ja not_active Withdrawn
- 2007-11-12 CA CA002668603A patent/CA2668603A1/en not_active Abandoned
- 2007-11-12 WO PCT/EP2007/009765 patent/WO2008055702A1/en active Application Filing
- 2007-11-12 EP EP07819754A patent/EP2101814A1/en not_active Withdrawn
- 2007-11-12 BR BRPI0719005-0A patent/BRPI0719005A2/pt not_active IP Right Cessation
- 2007-11-12 BR BRPI0718796-3A2A patent/BRPI0718796A2/pt not_active IP Right Cessation
- 2007-11-12 EA EA200970471A patent/EA025395B1/ru not_active IP Right Cessation
- 2007-11-12 US US12/514,248 patent/US9494587B2/en active Active
- 2007-11-12 ES ES07819755T patent/ES2715045T3/es active Active
- 2007-11-12 NZ NZ577559A patent/NZ577559A/en not_active IP Right Cessation
- 2007-11-12 JP JP2009535632A patent/JP5771355B2/ja not_active Expired - Fee Related
- 2007-11-12 RU RU2009122204/10A patent/RU2460074C2/ru not_active IP Right Cessation
- 2007-11-12 AU AU2007316820A patent/AU2007316820B2/en not_active Ceased
- 2007-11-12 WO PCT/EP2007/009766 patent/WO2008055703A2/en active Search and Examination
- 2007-11-12 MX MX2009005004A patent/MX2009005004A/es active IP Right Grant
- 2007-11-12 KR KR1020157011383A patent/KR20150054014A/ko not_active IP Right Cessation
- 2007-11-12 CN CN200780049283.7A patent/CN101573138B/zh active Active
- 2007-11-12 US US12/514,200 patent/US8592165B2/en not_active Expired - Fee Related
- 2007-11-12 CA CA002668704A patent/CA2668704A1/en not_active Abandoned
- 2007-11-12 EP EP07819755.5A patent/EP2099480B2/en active Active
- 2007-11-12 AU AU2007316819A patent/AU2007316819B2/en not_active Ceased
- 2007-11-12 KR KR1020097011972A patent/KR20090080554A/ko not_active Application Discontinuation
-
2009
- 2009-05-04 NO NO20091748A patent/NO20091748L/no not_active Application Discontinuation
- 2009-05-05 IL IL198567A patent/IL198567A0/en unknown
- 2009-05-07 IL IL198626A patent/IL198626A/en not_active IP Right Cessation
-
2010
- 2010-03-30 HK HK10103304.3A patent/HK1136219A1/xx not_active IP Right Cessation
-
2015
- 2015-04-01 JP JP2015074801A patent/JP2015133979A/ja not_active Withdrawn
- 2015-04-01 JP JP2015075105A patent/JP2015134813A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200970471A1 (ru) | Микроорганизмы или их фракции, обеспечивающие активацию клеточного иммунитета против углеводов | |
NL301145I2 (nl) | Tirbanibulin | |
EA201001372A1 (ru) | Формы рифаксимина и их применение | |
EA200970737A1 (ru) | Оксабициклогептаны и оксабициклогептены, их получение и применение | |
MX2010004219A (es) | Agentes de enlace de cd19 y usos de los mismos. | |
EA201101521A1 (ru) | Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния | |
MX2009006536A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. | |
WO2006127900A3 (en) | Tl1a in the treatment of disease | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
WO2006102504A3 (en) | Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors | |
WO2007092622A3 (en) | Compositions and methods for treating bone | |
EA201300242A1 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
MXPA06014510A (es) | Composiciones y metodos para tratar trastornos inflamatorios. | |
TW200740844A (en) | Novel MAdCAM antibodies | |
MX2009008104A (es) | Hepcidina, antagonistas de hepcidina y metodos de uso. | |
EA201200977A1 (ru) | Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами | |
TR200906131T1 (tr) | Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e | |
EA200701995A1 (ru) | Способы уменьшения кальцификации | |
GB0515353D0 (en) | Food | |
EA200700717A1 (ru) | Сульфонамиды | |
BRPI0712607A8 (pt) | métodos de tratamento de acidente vascular cerebral | |
TNSN08400A1 (en) | Organic compounds and their uses | |
EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
WO2011035205A3 (en) | Antibodies against candida, collections thereof and methods of use | |
EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |